PharmiWeb.com - Global Pharma News & Resources
31-Mar-2023

Lonza Launches Share Buyback Program of up to CHF 2 Billion

Lonza Group AG / Key word(s): Corporate Action
Lonza Launches Share Buyback Program of up to CHF 2 Billion
31.03.2023 / 07:00 CET/CEST

Basel, Switzerland, 31 March 2023 – On 3 April 2023, Lonza will launch a share buyback program of up to CHF 2 billion, as announced on 25 January 2023. Enabled by Lonza’s strong balance sheet and positive outlook, the share buyback program aims to return excess capital to shareholders without impacting the company’s capability to invest in organic growth and bolt-on M&A. At the same time, Lonza remains committed to maintaining its strong investment grade rating.

The volume of monthly share buybacks will depend on market conditions. The registered shares of Lonza Group Ltd. will be repurchased via a second trading line on the SIX Swiss Exchange for the purpose of a capital reduction.

Please visit the Share Buyback webpage for additional information.

About Lonza
Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell & Gene and Capsules & Health Ingredients. Our unparalleled breadth of offerings across divisions enables our customers to commercialize their discoveries and innovations in the healthcare industry.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 17,500 full-time employees, we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 6.2 billion with a CORE EBITDA of CHF 2.0 billion in Full-Year 2022. Find out more at www.lonza.com

Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter

Lonza Contact Details

Victoria Morgan
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 2283
victoria.morgan@lonza.com

Lyle Wheeler
Investor Relations
Lonza Group Ltd
Tel +41 79 154 9522
lyle.wheeler@lonza.com

Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Privacy Policy link

To immediately delete all the data



End of Media Release


Language: English
Company: Lonza Group AG
Münchensteinerstrasse 38
4052 Basel
Switzerland
Phone: +4161 316 81 11
Internet: www.lonza.com
ISIN: CH0013841017
Valor: 1384101
Listed: SIX Swiss Exchange
EQS News ID: 1597731

 
End of News EQS News Service

Editor Details

Last Updated: 31-Mar-2023